MedWatch

Novo expects GLP-1 products to drive diabetes business growth

Drugs like Rybelsus and Ozempic are predicted to have the most impact on the growth of Novo Nordisk’s diabetes treatments, the company reveals on its capital markets day.

Executive Vice President for Commercial Strategy and Corporate Affairs Camilla Sylvest | Photo: Novo Nordisk / PR

Novo Nordisk now has a 30.3 percent share of the diabetes market, and is well on the way to achieving its long-term goal of controlling a third of the market. In 2019, the company’s market share was 28 percent.

Executive Vice President for Commercial Strategy and Corporate Affairs Camilla Sylvest mentioned this goal at Novo’s capital markets day, saying that over the next few years, growth is expected to be driven by GLP-1 products like tablet Rybelsus and the company’s best-selling drug Ozempic.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs